Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 10/20 | 0.35 |
| ▸ | CX3CR1 | P49238 | 10/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309194 | 0.90 | JAK2 (0.42) | JAK2KCNH2CXCR2CX3CR1 | |
| SCHEMBL3314132 | 0.89 | JAK2 (0.41) | JAK2KCNH2CXCR2CX3CR1 | |
| SCHEMBL3314333 | 0.87 | JAK2 (0.46) | JAK2KCNH2 | |
| SCHEMBL2358845 | 0.85 | JAK2 (0.47) | JAK2KCNH2 | |
| SCHEMBL3302099 | 0.84 | JAK2 (0.46) | JAK2KCNH2 | |
| SCHEMBL3311138 | 0.84 | JAK2 (0.42) | JAK2KCNH2 | |
| SCHEMBL3315384 | 0.84 | JAK2 (0.46) | JAK2KCNH2 | |
| SCHEMBL3312839 | 0.84 | JAK2 (0.46) | JAK2KCNH2 | |
| SCHEMBL3309001 | 0.84 | JAK2 (0.46) | JAK2KCNH2 | |
| SCHEMBL2356551 | 0.79 | JAK2 (0.41) | JAK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | claimed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | claimed |
| US-20200093825-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2020-03-26 | — | — | US | disclosed |
| US-20170087158-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2017-03-30 | — | — | US | disclosed |
| EP-3042655-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | Incyte Holdings Corporation (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20120301464-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2012-11-29 | — | — | US | disclosed |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087158-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | JAK2 3/4885KCNH2 2157/4885CXCR2 1174/4885 |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | JAK2 2/4885KCNH2 2790/4885CXCR2 1014/4885 |
| US-20120301464-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | JAK2 3/4885KCNH2 3148/4885CXCR2 794/4885 |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | JAK2 3/4885KCNH2 3148/4885CXCR2 794/4885 |
| US-20200093825-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | JAK2 3/4885KCNH2 3148/4885CXCR2 794/4885 |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | JAK1, JAK2, JAK3 | JAK2 2/4885KCNH2 2790/4885CXCR2 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.